Hybrigenics: H117 Results Released, Business On Track
Edison | Nov 15, 2017 06:18AM ET
Hybrigenics (PA:ALHYG) has reported H117 financial results which have been restated to reflect the sale of the proteomics division. Hybrigenics continues to generate preclinical data from its inhibitors of ubiquitin-specific protease (USP) programme. Inecalcitol’s Phase II studies in acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML) will be expanded to other countries and combinations with other kinase inhibitors, respectively. Net cash at end July 2017 was €11m which we estimate provides runway into 2019. Our updated valuation is €129m or €2.75/share.
Company reports H117 results; forecasts adjusted
Hybrigenics reported the results of its retained activities (inecalcitol development, the research on USP inhibitors and its genomic services division Helixio) following the R&D reorganisation and sale of the majority of its proteomics services division for €0.8m in March 2017. Revenues from retained activities were €1.2m in H117 vs €1m in H116. Operating costs were €4.7m vs €3.5m in H116 largely due to the Phase II clinical trial of inecalcitol in AML. We have adjusted FY17e total revenue to €2.5m (vs €3.7m previously) and increased FY17 expenses to €10.1m (from €8m) to reflect the expansion of the Phase II trials. After raising €6.8m in June 2017, pro forma cash at 24 July 2017 was €11m, sufficient to fund operations into 2019.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.